A study in patients with chronic GVHD evaluated three doses of axatilimab, a colony-stimulating factor 1 receptor antibody. The lowest dose appeared to maximize response with the fewest adverse effects.
The New England Journal of Medicine: Search Results in Hematology/Oncology
